LZTR1 and Miyoshi myopathy: Comparing these genes with KRAS interaction partners (≥1.0 log2 fold enrichment)14 and tumor suppressor genes in RAS-dependent MM lines (CSS≥0.5)19 identified LZTR1 (Fig. 3C).